INmune Bio Return On Asset vs. Revenue
| INMB Stock | USD 4.87 0.38 7.24% |
For INmune Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of INmune Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well INmune Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between INmune Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of INmune Bio over time as well as its relative position and ranking within its peers.
INmune |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
INmune Bio Revenue vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining INmune Bio's current stock value. Our valuation model uses many indicators to compare INmune Bio value to that of its competitors to determine the firm's financial worth. INmune Bio is rated below average in return on asset category among its peers. It is rated below average in revenue category among its peers . At present, INmune Bio's Total Revenue is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the INmune Bio's earnings, one of the primary drivers of an investment's value.INmune Revenue vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
INmune Bio |
| = | -0.45 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
INmune Bio |
| = | 155 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
INmune Revenue vs Competition
INmune Bio is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 389.34 Million. INmune Bio adds roughly 155,000 in revenue claiming only tiny portion of equities under Health Care industry.
INmune Bio Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in INmune Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, INmune Bio will eventually generate negative long term returns. The profitability progress is the general direction of INmune Bio's change in net profit over the period of time. It can combine multiple indicators of INmune Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -799 K | -759 K | |
| Operating Income | -29.7 M | -28.3 M | |
| Net Loss | -27.4 M | -26.1 M | |
| Income Before Tax | -30 M | -28.5 M | |
| Total Other Income Expense Net | -267 K | -280.4 K | |
| Net Loss | -24.6 M | -23.3 M | |
| Net Loss | -30 M | -28.5 M | |
| Income Tax Expense | -29.7 M | -28.3 M | |
| Net Interest Income | 69.9 K | 62.2 K | |
| Interest Income | 69.9 K | 62.2 K | |
| Non Operating Income Net Other | -1.1 M | -1 M | |
| Change To Netincome | 8.2 M | 8.6 M | |
| Net Loss | (1.67) | (1.75) | |
| Income Quality | 0.40 | 0.76 | |
| Net Income Per E B T | 1.21 | 1.23 |
INmune Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on INmune Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of INmune Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the INmune Bio's important profitability drivers and their relationship over time.
Use INmune Bio in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INmune Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INmune Bio will appreciate offsetting losses from the drop in the long position's value.INmune Bio Pair Trading
INmune Bio Pair Trading Analysis
The ability to find closely correlated positions to INmune Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INmune Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INmune Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling INmune Bio to buy it.
The correlation of INmune Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INmune Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if INmune Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INmune Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your INmune Bio position
In addition to having INmune Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Baby Boomer Prospects Thematic Idea Now
Baby Boomer Prospects
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
To fully project INmune Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of INmune Bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include INmune Bio's income statement, its balance sheet, and the statement of cash flows.